Condition: Idiopathic Hyperaldosteronism · Hyperaldosteronism · Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
This description comes directly from the study's public registry record.
Xiongjing Jiang, MD · 86-010-88322387 · jxj103@hotmail.com
Hui Dong, MD · 86-010-88322387 · donghui666@sina.com
Always discuss trial participation with your own doctor first.
| Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
| Second Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| The First Affiliated Hospital of Chengdu Medical College | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07328230